Targeting TAMs and their specific secreted factors, such as CXCL7 in CRC and S100A9 in lung adenocarcinoma, could therefore offer a strategy to intervene in resistance mechanisms tailored to different tumor types. This evidence concerns the gene S100A9 and colorectal carcinoma.